Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.
Newlands
E S
ES
Department of Medical Oncology, Charing Cross Hospital, London, U.K.
Stevens
M F
MF
Wedge
S R
SR
Wheelhouse
R T
RT
Brock
C
C
D000328:Adult; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000737:chemistry / Q000494:pharmacology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009374:Neoplasms, Experimental / Q000188:drug therapy; D000077204:Temozolomide; D014407:Tumor Cells, Cultured / Q000187:drug effects
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide